916737-76-3

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Bromo-3-methoxy-2-nitro-pyridine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Organic Compounds Synthesis:
6-Bromo-3-methoxy-2-nitro-pyridine is utilized as a building block in the creation of other organic compounds, leveraging its unique structure and functional groups to form a variety of chemical entities.
Used in Antimicrobial Applications:
6-Bromo-3-methoxy-2-nitro-pyridine is employed for its antimicrobial properties, serving as a potential agent in the development of treatments against bacterial infections.
Used in Antifungal Applications:
6-Bromo-3-methoxy-2-nitro-pyridine is also used for its antifungal properties, indicating its potential use in formulations to combat fungal infections.
Used in Research and Development Laboratories:
6-Bromo-3-methoxy-2-nitro-pyridine is used in research settings to explore its unique chemical properties and to study its interactions with other compounds, which can lead to advancements in chemical science and technology.
Used in Commercial Chemical Applications:
6-Bromo-3-methoxy-2-nitro-pyridine is widely available for purchase, making it accessible for a range of commercial applications where its specific chemical characteristics are beneficial.

InChI:InChI=1/C6H5BrN2O3/c1-12-4-2-3-5(7)8-6(4)9(10)11/h2-3H,1H3

Upstream product

• 74-88-4 methyl iodide 
• 20265-37-6 3-methoxy-2-nitropyridine 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 443956-08-9 6-bromo-2-nitropyridin-3-ol 

Downstream Products

• 952289-01-9 cis-3,5-dimethyl-1-[5-(methyloxy)-6-nitro-2-pyridinyl]piperazine 
• 443956-08-9 6-bromo-2-nitropyridin-3-ol 
• 1454926-07-8 3-{3-[4-(6-amino-5-methoxy-(2-pyridyl))phenyl]propyl}-1-{[4-(tert-butyl)phenyl]methyl}-4-ethyl-4,5-dihydro-1H-1,2,4-triazolin-5-one 
• 1454926-08-9 1-{[4-(tert-butyl)phenyl]methyl}-4-ethyl-3-[3-(4-{5-methoxy-6-[(phenylsulfonyl)amino](2-pyridyl)}phenyl)propyl]-4,5-dihydro-1H-1,2,4-triazolin-5-one 
• 1454926-60-3 1-{[4-(tert-butyl)phenyl]methyl}-4-ethyl-3-[3-(4-{5-methoxy-6-[N-methyl(phenylsulfonyl)amino](2-pyridyl)}phenyl)propyl]-4,5-dihydro-1H-1,2,4-triazolin-5-one 
• 953392-43-3 N₁-[6-({[3-fluoro-4-(5-methyl-2-furanyl)phenyl]sulfonyl}amino)-5-(methyloxy)-2-pyridinyl]-2-methylalaninamide hydrochloride 
• 953392-13-7 1,1-dimethylethyl (2-{[6-{[(4-bromo-3-fluorophenyl)sulfonyl]amino}-5-(methyloxy)-2-pyridinyl]amino}-1,1-dimethyl-2-oxoethyl)carbamate 
• 1454928-28-9 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(4-(5-methoxy-6-nitropyridin-2-yl)phenyl)propyl)-1H-1 ,2,4-triazol-5(4H)-one 
• 1438286-83-9 3-methoxy-6-(1-(3,4,5-trimethoxyphenyl)vinyl)pyridin-2-amine 
• 1438286-71-5 3-methoxy-2-nitro-6-(1-(3,4,5-trimethoxyphenyl)vinyl)pyridine 
• 916737-77-4 6-bromo-3-methoxypyridin-2-amine 

Relevant academic research and scientific papers

OREXIN RECEPTOR ANTAGONISTS

The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

An efficient coupling of N-tosylhydrazones with 2-halopyridines: Synthesis of 2-α-styrylpyridines endowed with antitumor activity

The synthesis of 2-α-styrylpyridines has been carried out by using the coupling of polyoxygenated N-tosylhydrazones with various 2-halopyridines. We demonstrated that the use of a catalytic amount of PdCl2(MeCN) 2 in combination with a bidentate ferrocene DPPF or a monodentate alkyl phosphine tBu2MeP-HBF4 constitutes an efficient protocol for this coupling, providing 2-α-styrylpyridines 2 in satisfactory to good yields. Among several polyoxygenated derivatives 2 evaluated, compound 2aa was found to exhibit excellent antiproliferative and antimitotic activities comparable to that of the reference compound isoCA-4. The Royal Society of Chemistry 2013.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

The design of efficient and selective routes to pyridyl analogues of 3-oxo-3,4-dihydro-2H-1,4-(benzothiazine or benzoxazine)-6-carbaldehydes

This Letter describes the synthesis of challenging pyridyl analogues of 3-oxo-3,4-dihydro-2H-1,4-(benzothiazine or benzoxazine)-6-carbaldehydes. The six different routes described are high yielding, contain no major purification issues and have been used to give gram quantities of each aldehyde.

NOVEL COMPOUNDS

The present invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.

ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS

The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.